Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,140.02% | 341.34% | 317.96% | -155.23% | -121.46% |
| Total Depreciation and Amortization | -4.88% | -2.64% | 3.36% | 18.88% | 39.81% |
| Total Amortization of Deferred Charges | 0.00% | 33.33% | 100.00% | 300.00% | -- |
| Total Other Non-Cash Items | -80.79% | -69.51% | 79.06% | 574.26% | 291.25% |
| Change in Net Operating Assets | -84.11% | -887.16% | -191.89% | -155.59% | -27.51% |
| Cash from Operations | 218.53% | 228.53% | 427.25% | 628.73% | 330.46% |
| Capital Expenditure | 43.04% | -0.56% | 36.00% | 32.96% | -100.72% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | 618.95% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 100.00% | 100.00% | -- |
| Cash from Investing | 61.43% | 37.46% | 56.19% | 61.39% | -196.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -449.24% | -329.23% | -408.09% | -505.40% | -27.86% |
| Issuance of Common Stock | 1,551.30% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -423.47% | -305.41% | -389.97% | -502.96% | -124.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 337.35% | 413.20% | 1,751.66% | 2,164.77% | 699.59% |